time to time. 1.26 "Marketing Authorization" shall mean an application to the appropriate Regulatory Authority for approval to market the Product in any particular jurisdiction and all amendments and supplements thereto 1.27 "Minimum Order Requirements" shall mean multiples of a full Batch. 1.28 "Pack" shall mean a bottle containing either **** or **** tablets of the Product, Labeled with the Livery. 1.29 "Packaging" shall mean all primary containers (including bottles or blisters) for the Product, plus cardboard cartons, PILs, shipping cases or any other like matter used in packaging and/or accompanying the Product. 3 Source: KITOV PHARMA LTD., 20-F, 3/26/2019 1.30 "Person" means any individual, entity or corporation of any kind, domiciled in any jurisdiction. 1.31 "Product" shall mean tablets containing the APIs Celecoxib/Amlodipine in three dosage strengths (200/10mg, 200/5mg and 200/2.5mg), Labelled with the Livery and in Packs. 1.32 "Quality Agreement" shall mean the agreement to be entered into by the Parties pursuant to Section ​4.1 below, which allocates the pharmaceutical responsibilities and obligations of the Parties with respect to Product quality. 1.33 "Quarter" shall mean the relevant three (3) month period ending on 31 March, 30 June, 30 September and 31 December in any calendar year, and any shorter period commencing on a day following the end of a Quarter and ending on the expiration or termination of this Agreement. 1.34 "Regulatory Authority" shall mean, in a particular country or jurisdiction, any applicable governmental authority involved in granting a Marketing Authorization in such country or jurisdiction, including, inter alia, the FDA and EMA. 1.35 "Specifications" shall mean the pharmacochemical, manufacturing, stability and other specifications of a Product defined in such Product's Marketing Authorization, subject to change from time to time as reasonably required to meet any requirements of the relevant Health Authorities. 1.36 "Supply Commencement Date" shall mean